6E5.F NORDHEALTH AS NK 1
- Market cap
- EUR 186M
- P/E
- -
- P/B
- 3.24x
- ROE
- -32.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6E5.F undervalued?
Graham numberThe Graham number of NORDHEALTH AS NK 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NORDHEALTH AS NK 1 fundamental analysis
No fundamental analysis for NORDHEALTH AS NK 1 yet.
NORDHEALTH AS NK 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NORDHEALTH AS NK 1
Nordhealth AS provides healthcare software solutions in Norway, Finland, Sweden, the United Kingdom, Denmark, DACH, and internationally. Its products include Provet, a practice management software platform for veterinary clinics and enterprise groups, providing appointment scheduling, patient management, electronic health records, billing and invoicing, reporting and analytics, government compliance tools, communication features, inventory management, and workflow automation…
Full company profileNORDHEALTH AS NK 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NORDHEALTH AS NK 1 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 20.3M | 31.0M | 36.8M | 45.7M | 50.8M | 55.3M |
| Gross Profit | 16.7M | 26.3M | 31.7M | 39.0M | 41.3M | 42.8M |
| Operating Income | -4.46M | -14.7M | -11.4M | -7.73M | -12.5M | -16.8M |
| EBITDA | - | -5.41M | -659K | 4.21M | -965K | -4.94M |
| Net Income | -4.73M | -14.3M | -11.1M | -7.67M | -12.7M | -18.0M |
| EPS | -0.06 | -0.18 | -0.14 | -0.10 | -0.16 | -0.23 |
| Balance Sheet | ||||||
| Total Assets | 125M | 115M | 91.9M | 83.0M | 71.5M | 68.8M |
| Total Liabilities | 10.6M | 16.3M | 9.17M | 9.33M | 9.97M | 13.8M |
| Shareholders' Equity | 115M | 98.6M | 82.8M | 73.6M | 61.6M | 55.0M |
| Cash & Short-term Investments | 26.2M | 15.5M | 5.05M | 4.10M | 4.36M | 5.77M |
| Cash Flow | ||||||
| Operating Cash Flow | 5.57M | -6.30M | -5.22M | 1.85M | 719K | 476K |
| Capital Expenditure | 3.38M | 6.80M | 5.72M | 5.02M | 5.09M | 4.88M |
| Free Cash Flow | 2.19M | -13.1M | -10.9M | -3.17M | -4.37M | -4.40M |
| Ratios | ||||||
| ROE | -4.1% | -14.5% | -13.4% | -10.4% | -20.6% | -32.6% |
| ROA | -3.8% | -12.4% | -12.1% | -9.2% | -17.7% | -26.1% |
| Net Profit Margin | -23.3% | -45.9% | -30.2% | -16.8% | -24.9% | -32.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NORDHEALTH AS NK 1 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | EUR 3.73M | 0.05 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NORDHEALTH AS NK 1
- Insiders 6.17%
- Institutions 8.81%
- Public & others 85.03%
- Shares outstanding 44.2M
- Free float 42.1M
NORDHEALTH AS NK 1 company profile
- Company name
- NORDHEALTH AS NK 1
- Ticker
- 6E5.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Information Services
- Employees
- 447
- Fiscal year end
- December
- Address
- Hasleveien 28A, Oslo, Norway, 0571
- Website
- nordhealth.com
About NORDHEALTH AS NK 1
Nordhealth AS provides healthcare software solutions in Norway, Finland, Sweden, the United Kingdom, Denmark, DACH, and internationally. Its products include Provet, a practice management software platform for veterinary clinics and enterprise groups, providing appointment scheduling, patient management, electronic health records, billing and invoicing, reporting and analytics, government compliance tools, communication features, inventory management, and workflow automation; Diarium, a PMS for therapists that streamlines therapy sessions, booking, and invoicing; Physica, a PMS for physiotherapists; Psykbase, a PMS for psychologists and psychiatrists; EasyPractice, a PMS for therapists; and various PMS for veterinarians under the Vetserve, Sanimalis, Vetvision, and Vetera names. The company's products comprise Nordhealth Connect, a communication platform for patients and healthcare professionals; and Navisec, a digital learning environment for training and orientation. In addition, it offers services related to the implementation of SaaS systems, such as consultancy services, education, and data conversion. Further, the company provides nordhealth.fi, a consumer booking portal. Nordhealth AS was founded in 2001 and is based in Oslo, Norway.
NORDHEALTH AS NK 1 management
5- Mr. Charles MacBainGroup Chief Executive Officer
- Alexander CramGroup Chief Financial Officer
- Dr. James StanierChief Technology Officer
- Mr. Janne Heikki HuttunenChief Innovation Officer of Veterinary & Board Member
- Mr. Karan WalliaCEO of the Therapy Business Unit